# Attenuating pulmonary injury and inflammation with C5/CD14 inhibition therapy: results from a porcine polytrauma model with blunt chest trauma

**Authors:** Ümit Mert, Rald V. M. Groven, Kang Qin, Johannes Greven, Elizabeth Rosado Balmayor, Tom Eirik Mollnes, Markus Huber-Lang, Martijn van Griensven, Frank Hildebrand, Klemens Horst

PMC · DOI: 10.1007/s00068-026-03157-w · European Journal of Trauma and Emergency Surgery · 2026-03-24

## TL;DR

A porcine study shows that blocking C5/CD14 reduces lung damage and inflammation after chest trauma, potentially preventing complications like ARDS.

## Contribution

Demonstrates that C5/CD14 inhibition reduces pulmonary injury and inflammation in a polytrauma model.

## Key findings

- C5/CD14 inhibition significantly reduced lung tissue damage compared to trauma groups.
- Proinflammatory cytokine levels in alveolar macrophages were lower in the C5/CD14 inhibition group.
- Lung injury scores and wet/dry ratios were closer to control levels in the C5/CD14 inhibition group.

## Abstract

Thoracic injury is prevalent among polytrauma patients, affecting up to 45% of these patients and often leading to complications such as pulmonary dysfunction up to acute respiratory distress syndrome (ARDS). This study investigates the impact of surgical invasiveness and C5/CD14 inhibition therapy on pulmonary tissue damage and the local immune response of the lungs in a porcine polytrauma model.

A post hoc analysis focusing on the pulmonary consequences of blunt thoracic trauma and multiple trauma was performed in a previously published porcine trauma model, in presence or absence of immunomodulation. A control group (n = 6; CG) was used that received identical instrumentation, anesthesia, nutrition, and fluid intake, but no trauma. For the trauma model, male pigs underwent a standardized polytrauma, followed by allocation into three treatment groups: early total care (n = 8; ETC), damage control orthopedics (n = 8; DCO), and ETC with C5/CD14 inhibition (n = 4). Pulmonary histopathological changes were assessed at 72 h after trauma through lung injury scores and wet/dry ratios, while ex vivo cytokine expressions from isolated alveolar macrophages (AMs) were analyzed using enzyme-linked immunosorbent assays.

Histological results revealed significant lung damage in both the ETC and DCO groups compared to the control as well as the C5/CD14 inhibition group. The addition of C5/CD14 inhibition significantly lessened lung tissue damage, as indicated by lower lung injury scores and wet/dry ratios. Cytokine assays showed that AMs from the ETC + C5/CD14 group exhibited significantly decreased levels of proinflammatory cytokines compared to the other trauma groups, while showing similar cytokine expression levels as compared to the control group.

Early double blockade of C5/CD14 effectively mitigates pulmonary tissue damage and post-traumatic inflammatory responses in lung tissue. This might result in reduced complications like ARDS and facilitating earlier definitive surgical interventions. These findings underscore the potential importance of immunomodulation strategies in managing post-traumatic outcomes and highlight the need for further research into their clinical applications in polytrauma settings.

## Linked entities

- **Proteins:** C5 (complement C5), CD14 (CD14 molecule)
- **Diseases:** acute respiratory distress syndrome (MONDO:0006502)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CD14 (CD14 molecule) [NCBI Gene 929], Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, CD14 [NCBI Gene 100620530], Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Cd14 (CD14 antigen) [NCBI Gene 12475], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}
- **Diseases:** sepsis (MESH:D018805), acute lung injury (MESH:D055371), analgesia (MESH:D000699), femur fractures (MESH:D000092524), multiple (MESH:D009104), Orthopedics (MESH:D009140), hemorhagic shock (MESH:D012769), hemorrhagic shock (MESH:D012771), C3 (MESH:C565169), pulmonary inflammatory (MESH:D016726), edema (MESH:D004487), inflammation (MESH:D007249), cardiorespiratory failure (MESH:D051437), Thoracic injury (MESH:D013898), thoracic trauma (MESH:D013896), ETC (MESH:D003428), pulmonary edema (MESH:D011654), pulmonary contusion (MESH:D003288), storm (MESH:C566109), lung inflammation (MESH:D011014), bleed (MESH:D006470), injuries (MESH:D014947), lung damage (MESH:D008171), femoral fracture (MESH:D005264), ARDS (MESH:D012128), pulmonary dysfunction (MESH:D011660), Damage (MESH:D020263), organ damage (MESH:D000092124), LIS (MESH:D055370)
- **Chemicals:** penicillin (MESH:D010406), paraffin (MESH:D010232), CO2 (MESH:D002245), hematoxylin (MESH:D006416), LPS (MESH:D008070), azaperone (MESH:D001376), oxygen (MESH:D010100), streptomycin (MESH:D013307), DCO (-), propofol (MESH:D015742), Midazolam (MESH:D008874), paraformaldehyde (MESH:C003043), eosin (MESH:D004801), ceftriaxone (MESH:D002443), Fentanyl (MESH:D005283)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013225/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013225/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC13013225/full.md

---
Source: https://tomesphere.com/paper/PMC13013225